Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FHND1002 Phase II Trial in Amyotrophic Lateral Sclerosis
ChiCTR2500109483Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of FHND1002 in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Peking University Third Hospital. Primary endpoint: Change from Baseline in ALSFRS-R Total Score at Week 48. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
FHND1002
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ChiCTR2500109483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109483.